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Abstract
Objective To examine risk of malignancy and death in patients with
kidney transplant who receive the immunosuppressive drug sirolimus.
Design Systematic review and meta-analysis of individual patient data.
Data sources Medline, Embase, and the Cochrane Central Register of
Controlled Trials from inception to March 2013.
Eligibility Randomized controlled trials comparing immunosuppressive
regimens with and without sirolimus in recipients of kidney or combined
pancreatic and renal transplant for which the author was willing to provide
individual patient level data. Two reviewers independently screened
titles/abstracts and full text reports of potentially eligible trials to identify
studies for inclusion. All eligible trials reported data on malignancy or
survival.
Results The search yielded 2365 unique citations. Patient level data
were available from 5876 patients from 21 randomized trials. Sirolimus
was associated with a 40% reduction in the risk of malignancy (adjusted
hazard ratio 0.60, 95% confidence interval 0.39 to 0.93) and a 56%
reduction in the risk of non-melanoma skin cancer (0.44, 0.30 to 0.63)
compared with controls. Themost pronounced effect was seen in patients
who converted to sirolimus from an established immunosuppressive
regimen, resulting in a reduction in risk of malignancy (0.34, 0.28 to
0.41), non-melanoma skin cancer (0.32, 0.24 to 0.42), and other cancers
(0.52, 0.38 to 0.69). Sirolimus was associated with an increased risk of
death (1.43, 1.21 to 1.71) compared with controls.
Conclusions Sirolimus was associated with a reduction in the risk of
malignancy and non-melanoma skin cancer in transplant recipients. The
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benefit was most pronounced in patients who converted from an
established immunosuppressive regimen to sirolimus. Given the risk of
mortality, however, the use of this drug does not seem warranted for
most patients with kidney transplant. Further research is needed to
determine if different populations, such as those at high risk of cancer,
might benefit from sirolimus.
Introduction
Kidney transplantation is the treatment of choice for people
with end stage renal disease as it improves survival1 and quality
of life compared with dialysis.2 Success in transplantation has
occurred to a great extent by the introduction of more potent
immunosuppressive drugs. These drugs have reduced the
incidence of acute rejection from 50% in 1995 to less than 10%
today.3 In the United States alone there are more than 185 000
patients alive with a functioning kidney transplant; a number
that has more than doubled since 1995.3 Similar improvement
has been reported in Europe, Asia, and Australia.4 The downside
of this success is that more patients are at risk of
immunosuppressive side effects related to the drugs, with the
most serious being malignancy.5 The incidence of most cancers
increases substantially after kidney transplantation.5 6 In addition
to substantial patient morbidity, cancer accounts for 10-30% of
all deaths after transplant.7 8Non-melanoma skin cancers (basal
and squamous cell carcinoma) are by far the most common type
of cancer, occurring in up to a third of kidney transplant
recipients.9Unlike in the general population, squamous cell skin
cancers can be quite aggressive in transplant recipients, with a
high recurrence rate, metastasis, and death.10-12Reduction in the
incidence and complications associated with malignancy would
be a major advance for kidney transplant recipients.
Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor,
is an immunosuppressive drug used in kidney transplantation.
The mTOR pathway is a key regulator of cell growth and
survival, and this pathway is often dysregulated in many types
of malignancy.13 As such there has been interest in the use of
sirolimus to reduce the risk of cancer.14-16An observational study
of the early experience with mTOR inhibitors found a 60%
reduction in cancers for patients receiving an mTOR inhibitor
compared with those who received a calcineurin inhibitor.16
Results from randomized trials have not been as convincing. A
meta-analysis published by the Cochrane Renal Group in 2006
showed a non-significant trend toward a lower risk of
malignancy for patients treated with sirolimus.17Trials published
since then have produced conflicting results. Two small trials
have both shown a significant reduction in skin cancer after
conversion from a calcineurin inhibitor to sirolimus, but neither
showed a reduction in other types of malignancy.18 19 The
SYMPHONY study, one of the largest transplant trials, failed
to show a reduction in cancer for those randomized to
sirolimus.20 Intuitively, the reduction in cancer with sirolimus
should also lead to improved survival. The Cochrane
meta-analysis showed a possible trend towards improved
survival for patients treated with sirolimus compared with those
receiving a calcineurin inhibitor.17 This analysis, however, was
underpowered as they had data on only 631 patients from six
trials.17
We investigated the effect of sirolimus on development of cancer
and on survival among transplant recipients using data from
randomized trials. We hypothesized that sirolimus would be




We conducted a systematic review to identify all randomized
trials comparing immunosuppressive regimens with and without
sirolimus in recipients of kidney or combined pancreatic and
renal transplant. To be eligible, trials needed to collect data on
malignancy after transplantation and have a planned follow-up
period of at least three months. We searched Medline, Embase,
and the Cochrane Central Register of Controlled Trials from
inception to 19 March 2013. Two trained reviewers
independently screened titles/abstracts and full text reports of
potentially eligible trials to identify studies for inclusion. The
corresponding author of each eligible trial was contacted and
asked to provide individual patient data. All initial
communications with authors were based on a template
explaining the study and the data required. Two separate
reminders were sent two weeks apart unless we had received a
definitive response. Several trial datasets were provided directly
by Pfizer (previously Wyeth Pharmaceuticals).
Data and variables
From each author, we requested an anonymized dataset
describing study characteristics, patient characteristics,
transplantation details, and events recorded during the trial. We
classified malignancies as non-melanoma skin cancer (basal
cell or squamous cell carcinoma of the skin) or other cancer (all
other malignancies). When more than one type of malignancy
was recorded on the same day in the same patient, each type
was coded individually. We classified deaths by cause:
cardiovascular, infection, malignancy, respiratory,
gastrointestinal, sudden death, other, or unknown. The reviewers
determined classification of occurrence of malignancy and type
as well as cause of death without knowledge of treatment
assignment. The pooled data were validated against the original
trial publications for accuracy. We assessed study quality with
the Cochrane Collaboration’s tool for assessing risk of bias and
publication bias with funnel plots.
Study outcomes
The primary outcome was the development of any new
malignancy after randomization. This outcome included any
type of cancer (such as basal cell skin cancer, lymphoma, etc).
Secondary outcomes included non-melanoma skin cancer, other
cancer, and death. We did not consider any events recorded
outside of the context of the original trial (for example, during
an observational follow-up extension study). As a sensitivity
analysis we analyzed, in aggregate form, the pooled risk of
malignancy, non-melanoma skin cancer, and death from all
trials identified as eligible for inclusion. This included the trials
for which we obtained individual patient level data as well as
the trials for which we had only trial level aggregate data.
Statistical analyses
We used a modified intention to treat approach. All participants
were analyzed according to the group to which they were
originally randomized. We excluded randomized patients who
did not receive the study drug or did not undergo transplantation.
The primary analysis estimated the time to any first malignancy.
Similar analyses were performed for the secondary outcomes:
times to first non-melanoma skin cancer, to other cancer, and
to death. We pooled the individual patient level data and used
Kaplan-Meier curves to calculate survival. Cox proportional
hazards models were used to determine adjusted hazard ratios
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with 95% confidence intervals. All Cox models were adjusted
for trial, age, sex, geographic location of participant, and time
after transplantation to randomization, with individual studies
considered as having random effects. For analyses of time to
malignancy, participants were censored at death or the date of
last follow-up. For patient survival, participants were censored
at date of last follow-up. Given that trials had differing lengths
of follow-up, we performed a sensitivity analysis that censored
all participants at 24months. Subgroup analyses were performed
to evaluate the effect of sirolimus by trial design and drug
exposure. We examined conversion trials (in which sirolimus
replaced another immunosuppressive drug, most often a
calcineurin inhibitor, at some time point after transplantation)
separately from de novo trials (sirolimus started as the initial
treatment at the time of transplantation).We did not have patient
level data on sirolimus drug concentration so we used the
average drug concentration achieved or target drug concentration
from published trial reports to categorize studies as low dose
or high dose trials (below or above the median sirolimus drug
concentration of 10 ng/mL). We performed supplementary
subgroup analyses to examine the effect of sirolimus by type
of donor (living v dead) and the use of antibody induction
therapy (yes v no). Donor type and antibody induction therapy
were subgroups within a trial and not trial level characteristics.
We compared survival curves with the log rank test and
proportions with χ2 tests. We calculated the number needed to
treat and the number needed to harm for time to event data.21
All reported P values are two sided.
Results
Characteristics of the participants
We included 21 trials18-40 (6894 participants) and received
individual patient data for 5963 patients (two trials were unable
to provide individual patient data for 931 participants38 39). None
of the 21 trials included patients who had received a combined
pancreatic and renal transplant. Additionally, 87 participants
were excluded as they never received a transplant or did not
receive any study drug, leaving 5876 eligible patients. Figure
1⇓ outlines the search and selection of randomized controlled
trials for the review. Table 1⇓ shows the characteristics of the
patients. In the control group, only 156 patients received placebo
and the remaining 2444 received an active drug comparator.
The patients randomized to placebo also received cyclosporine
and prednisone. Table A in appendix 1 describes the features
of the 21 included trials including target drug concentrations.
Table B in appendix 1 outlines the risk of bias for each trial,
and figure A in appendix 2 shows the funnel plots for the
outcomes of cancer and death.
Primary analysis
In total 243 patients developed a malignancy: 127 in the
sirolimus group and 116 in the control group. The cumulative
incidence of cancer was lower in the sirolimus group than in
the control group (P=0.006; fig 2⇓). After multivariable
adjustment, the reduction in the risk of malignancy remained
significant (adjusted hazard ratio 0.60, 95% confidence interval
0.39 to 0.93; P=0.02) (table 2⇓). Each one year increment in
age was associated with a 6% increase risk of cancer (1.06, 1.04
to 1.09; P<0.001) (table 2). There was a 20% reduction in risk
of malignancy in women compared with men (0.80, 0.66 to
0.97; P=0.03) (table 2).
Geographic location of patient was associated with cancer.
Compared with patients in North America, those in Oceania
had a threefold increased risk of malignancy (3.68, 2.21 to 6.13;
P<0.001), while those living in Africa (0.31, 0.23 to 0.41;
P<0.001), Asia (0.87, 0.58 to 1.30; P=0.49), Europe (0.58, 0.44
to 0.76; P<0.001), and South America (0.59, 0.42 to 0.85;
P=0.004) had a lower risk of cancer (table 2⇓). Overall, the
causes of cancer were significantly different in the sirolimus
and control groups (P=0.004; table C in appendix 1). There was
a higher proportion of squamous (2.0% v 1.3%) and basal (1.4%
v 0.79%) cell skin cancer in the control group compared with
the sirolimus group, while there were more hematological
malignancies in the sirolimus group (0.64% v 0.19%).
Secondary analyses
The cumulative incidence of non-melanoma skin cancer was
significantly greater in the control arm than in the sirolimus
group (P<0.001; fig 3⇓). The reduction in non-melanoma skin
cancer for those receiving sirolimus remained significant after
multivariable adjustment (adjusted hazard ratio 0.44, 95%
confidence interval 0.30 to 0.63; P<0.001). There was no
significant difference in the occurrence of other cancers in those
receiving sirolimus compared with control (P=0.65; fig B in
appendix 2). Multivariable adjustment did not change this
association (1.05, 0.57 to 1.94; P=0.88).We carried out separate
analyses for sirolimus compared with placebo and sirolimus
compared with an active comparator, but the conclusions did
not differ for the outcomes of any cancer, non-melanoma skin
cancer, or other cancer (data not shown).
There were 202 deaths: 133 in the sirolimus group and 69 in
the control group (table D in appendix 1 and fig C in appendix
2). Overall patient survival was significantly reduced in the
sirolimus group (P=0.04; fig 4⇓). After multivariable adjustment,
sirolimus use was associated with a 43% increased risk of death
compared with the control group (adjusted hazard ratio 1.43,
1.21 to 1.71; P<0.001) (table 2⇓). The causes of death were
significantly different in the two groups (P=0.002; table D in
appendix 1). There were relatively few deaths attributed to
malignancy, but the proportions were similar in the two groups
(0.21% sirolimus, 0.19% control). There was a higher proportion
of death from infection (0.58% v 0.15%) and cardiovascular
disease (1.28% v 0.54%) in the sirolimus group compared with
the control group. There was a trend towards improved graft
survival after deaths were censored in the sirolimus patients
(P=0.06; fig D in appendix 2).
Subgroup analyses
In conversion trials, the cumulative incidence of cancer was
lower in the sirolimus group than in the control group (P<0.001;
fig E in appendix 2), which persisted after adjustment for
covariates. Patients receiving sirolimus had a 66% reduction in
the risk of cancer (adjusted hazard ratio 0.34, 95% confidence
interval 0.28 to 0.41; P<0.001) (fig 5⇓). Sirolimus use was
associated with a 68% reduction in the risk of non-melanoma
skin cancer (0.32, 0.24 to 0.42; P<0.001) and a 48% reduction
in the risk of other cancers (0.52, 0.38 to 0.69; P<0.001). As
with the overall analysis, sirolimus use was associated with an
increased risk of death in the conversion trials (1.59, 1.36 to
1.85; P<0.001) (fig 5⇓).
Patients in de novo trials showed different results with respect
to occurrence of cancer. Sirolimus use was not associated with
a reduced risk of cancer (adjusted hazard ratio 1.09, 95%
confidence interval 0.74 to 1.61; P=0.65) (fig 5⇓),
non-melanoma skin cancer (0.65, 0.36 to 1.17; P=0.15) (fig 5),
or other cancers (1.70, 0.98 to 2.93; P=0.06). Consistent with
the other analyses, sirolimus use was associated with a
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significant increase in the risk of death in de novo trials (1.39,
1.12 to 1.73; P=0.003) (fig 5).
In low dose sirolimus trials, there was no difference in the risk
of malignancy (adjusted hazard ratio 0.65, 95% confidence
interval 0.30 to 1.41; P=0.27), but there was a significant
reduction in non-melanoma skin cancer (0.43, 0.24 to 0.78;
P=0.006) (fig 5⇓) for patients taking sirolimus compared with
control. There was no significant difference in the risk of death
between the two groups (1.07, 0.81 to 1.41; P=0.65) (fig 5⇓).
In high dose sirolimus trials, there was a significant reduction
in the risk of malignancy (0.57, 0.36 to 0.91; P=0.02) and
non-melanoma skin cancer (0.43, 0.26 to 0.70; P<0.001) (fig
5) for patients taking sirolimus compared with control. Sirolimus
use was associated with an increased risk of death in the high
dose sirolimus trials (1.53, 1.15 to 2.05; P=0.004) (fig 5).
For patients who did not receive antibody induction therapy,
sirolimus use was associated with a non-significant reduction
in any cancer (adjusted hazard ratio 0.68, 95% confidence
interval 0.45 to 1.01) and a significant reduction in
non-melanoma skin cancer (0.35, 0.22 to 0.55) (fig F in appendix
2). Sirolimus use was associated with a significant increase in
other cancers (1.82, 1.25 to 2.65) and a null effect for death
(1.02, 0.77 to 1.34) for those who did not receive induction
therapy (fig F in appendix 2). For the antibody induction group
sirolimus use was associated with a non-significant increase in
any cancer (1.26, 0.61 to 2.61), non-melanoma skin cancer (1.42,
0.49 to 4.14), and other cancers (1.25, 0.39 to 3.98), with a
significant increase in death (1.90, 1.36 to 2.68) (fig F in
appendix 2).
For recipients of organs from both living and deceased donors,
the findings were consistent with the overall results for the
outcomes of any cancer, non-melanoma skin cancer, and other
cancer (fig F in appendix 2). For the outcome of death, sirolimus
use was associated with an increased risk of death in recipients
from deceased donors (adjusted hazard ratio 1.52, 95%
confidence interval 1.21 to 1.91), but there was a null effect in
recipients with living donors (1.00, 0.56 to 1.78) (fig F in
appendix 2).
Sensitivity analysis
As a sensitivity analysis we analyzed the trial level pooled risk
of malignancy, non-melanoma skin cancer, and death from all
trials identified as eligible for inclusion (table 3⇓). Of those that
reported only trial level data, 16 reported on cancer, nine
reported on non-melanoma skin cancer, and 29 reported death
(details of these trials are reported table E in appendix 2). The
pooled relative risk combinedwas 0.63 (95% confidence interval
0.48 to 0.81) for any cancer and 0.47 (0.37 to 0.61) for
non-melanoma skin cancer (table 3⇓). For the outcome of death,
when all trials were pooled together regardless of duration of
follow-up the relative risk was 1.21 (0.97 to 1.51). When we
confined the analysis to trials with greater than 24 months of
follow-up (n=11 trials; n=2507 patients), sirolimus use was
associated with a 42% increased risk of death compared with
the control group (1.42, 1.03 to 1.96).
Censoring of patients at 24 months did not have any material
effect on the study outcomes (table 4⇓). The use of sirolimus
remained associated with a significant reduction in any cancer
(adjusted hazard ratio 0.55, 95% confidence interval 0.32 to
0.94) and non-melanoma skin cancer (0.37, 0.22 to 0.62) and
an increased risk of death (1.38, 1.14 to 1.66) (table 4⇓). The
probability of survival at two years was 95.3% (95% confidence
interval 94.4% to 96.1%) for those receiving sirolimus compared
with 96.7% (95.7% to 97.5%) for those in the control group.
The two year cumulative incidence of cancer was 4.7% (3.8%
to 5.7%) and 7.5% (6.0% to 9.4%), respectively. The two year
cumulative incidence of non-melanoma skin cancer was 2.4%
(1.8% to 3.2%) and 5.0% (3.8% to 6.5%), respectively.
Discussion
Principal findings
This study included individual patient level data from 21
randomized trials comparing sirolimus with other
immunosuppressive regimens in 5876 recipients of kidney
transplant. There was a 40% reduction in the risk of malignancy
and a 56% reduction in risk of non-melanoma skin cancer for
those randomized to sirolimus. Patients in conversion trials
showed a significant reduction in non-melanoma skin cancer
as well as other cancers. In contrast, sirolimus patients enrolled
in de novo immunosuppression trials did not have a reduced
risk of malignancy or non-melanoma skin cancer principally
because of a non- significant increase in the risk of other types
of cancer. More importantly, despite the reduction in risk of
cancer seen in some patients, use of sirolimus was associated
with a significantly increased risk of death in both conversion
and de novo trial subgroups.
Although a reduction in cancer was seen in patients converted
to sirolimus, the increased risk of death highlights a concerning
consequence of this strategy that was not evident from previous
trials. By pooling individual patient data, we were able to
perform survival analyses, not just on occurrence of cancer but
also on overall survival of patients. Our findings help to clarify
the benefits and harms associated with sirolimus use regarding
reduction of malignancy after kidney transplantation. For
patients undergoing transplantation, the use of sirolimus as an
initial immunosuppressant cannot be recommended given the
lack of efficacy and increased risk of death. In contrast,
conversion of patients to sirolimus might reduce the risk of
cancer but at the increased cost of death. For every 1000 patients
converted to sirolimus and treated for two years, there would
be 95 fewer cases of non-melanoma skin cancer and 23 fewer
cases of other cancers, but 10 additional deaths. As we observed
no reduction in mortality related to cancer, the trade-off of fewer
cancers with an increased mortality does not seem justified.
Perhaps a subset of patients at greatest risk of cancer might
benefit from this strategy, but this would be difficult to predict
at the individual level and would require further investigation.
We evaluated several clinically important subgroups. Overall,
results were consistent with the main findings that included all
available trials and participants. Not surprisingly, there were a
few notable differences. For those who received induction
therapy, sirolimus use seemed to have no benefit with respect
to cancer reduction and was associated with a significant
increase risk of death. In patients who did not receive induction
therapy, however, there was a significant reduction in cancer
with no effect on mortality in those treated with sirolimus
(adjusted hazard ratio 1.02, 95% confidence interval 0.77 to
1.34). For recipients of a transplant from a deceased donor,
sirolimus was associated with a reduction in cancer and an
increased risk of death similar to the overall findings. For
recipients from living donors, however, sirolimus had a null
effect with respect to mortality (1.00, 0.56 to 1.78). Unlike the
trial level subgroups (for example, de novo or conversion)
patients were not randomized to treatment groups based on
induction therapy or donor type. This is an important distinction
as these subgroups might be imbalanced with respect to other
factors that could influence occurrence of cancer or death.While
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interesting clinically, the findings from these subgroup analyses
should be interpreted cautiously.
We could not identify the mechanism of cancer reduction in our
analysis. The greatest effect was seen in patients converted to
sirolimus from another immunosuppressant. Most of these
patients were converted from a calcineurin inhibitor, with the
remainder being switched from mycophenolate mofetil or
azathioprine. We did not have patient level data on drug
concentration to assess overall drug exposure, but we did see a
consistent effect on cancer reduction regardless of whether the
trial used high or low doses of sirolimus.Whether the reduction
in malignancy was because of an overall reduction in
immunosuppression, removal of oncogenic immunosuppression
(such as cyclosporine), or a combination of these factors remains
unknown.41
The excess risk of death associated with sirolimus could not be
directly explained by our data. We found an increase in both
cardiovascular deaths and deaths related to infection, the two
most common causes of death in patients with kidney
transplantation.7Over-immunosuppression with sirolimus could
have contributed to the increase in infection related mortality,
but this could not be confirmed without data on drug
concentration. We did, however, see a significantly increased
risk of death in the subgroup of trials that used high dose
sirolimus. Overall, net immunosuppression is increased in those
who experience acute rejection, given the need for additional
corticosteroids or more potent anti-lymphocyte drugs, or both.
Patients treated with sirolimus could have had higher net
immunosuppression because of the increased risk of acute
rejection seen in some of the included trials.20-23 This in turn
could have contributed to increased infection related mortality.
Sirolimus is known to have side effects that are associated with
an increased risk of cardiovascular disease, including anemia,20-37
proteinuria,37-43 hyperglycemia,37 44 and hyperlipidemia.20-45
Although we did not have relevant individual patient level data,
an increase in these known cardiac risk factors might have
contributed to the increase in cardiovascular death seen in our
analysis. It is important to note that death-censored graft survival
was not significantly different between the sirolimus and control
patients in our analysis. Thus, the increased risk of death was
not simply because of more deaths in patients who received
dialysis after graft failure, which has been well documented in
people with kidney transplant.46 47
Comparison with other studies
The results of this pooled analysis differ from those in previous
meta-analyses. Webster and colleagues observed a
non-significant trend towards less malignancy and death.17 The
discrepant findings are probably because of differences in
sample size and methods. The Webster review had outcome
data (dichotomized as yes/no without respect to timing after
transplantation) on only 447 patients for malignancy and 631
patients for survival. We had data (including event dates) on
5876 patients, which permitted survival analysis and increased
our statistical power to detect a difference. A second
meta-analysis48 examining calcineurin inhibitor sparing
regimens, which included a subgroup of trials involving
sirolimus, did not show any significant effect on patient survival
and did not report malignancy. Other sirolimus meta-analyses
have been published focusing on dyslipidemia45 and wound
complications,49 but neither reported on cancer or survival.45 49
The increased mortality observed in this analysis is consistent
with previous non-randomized studies.50-52 Isakova and
colleagues compared three groups: mTOR inhibitor (99%
sirolimus) without calcineurin inhibitor (n=3237), mTOR
inhibitor plus a calcineurin inhibitor (n=10 510) and calcineurin
inhibitor without mTOR inhibitor (n=125 623).52 Compared
with the calcineurin inhibitor group, themTOR inhibitor without
calcineurin inhibitor group had a 25% increased risk of death
and the mTOR inhibitor plus calcineurin inhibitor group had a
13% increased risk of death. The causes of death andmalignancy
data were not reported.52 In another analysis, immunosuppressive
regimens containing sirolimus had a risk of death that was
1.33-fold to 1.75-fold higher compared with other agents.50
Strengths and limitations of study
Our analysis does have some limitations. First, we did not have
access to patient level data from all randomized trials of
sirolimus in kidney transplantation. We performed an extensive
literature search to identify all relevant trials, but the
corresponding authors did not respond or agree to share data in
all cases. Nonetheless, we were still able to pool individual
patient level data on the largest number of randomized patients
treated with sirolimus to date. In addition, we pooled the risk
of cancer and death from all eligible trials, not just those from
which we had individual patient level data. In this meta-analysis
of aggregate data, the results were similar to our original analysis
and remained significant for the outcomes of any cancer and
non-melanoma skin cancer. There was a trend towards an
increased risk of death in the aggregate analysis (relative risk
1.21, 95% confidence interval 0.97 to 1.51) that became
significant when the analysis was restricted to studies with a
longer duration of follow-up (1.42, 1.03 to 1.96). Second, the
primary outcome was cancer in only one of the included trials.
Given the known association between immunosuppression and
malignancy, however, this adverse event is closely monitored
in transplantation trials and thus is not likely to be missed during
trial follow-up visits. In this analysis, cancer occurred in 4.1%
of patients, which is similar to what has been observed in other
transplant trials.53-55 Third, there was clinical heterogeneity in
the trials included in this analysis, as there often is in systematic
reviews. Various immunosuppressive regimens were used in
the trials, but all control patients received a calcineurin inhibitor
(cyclosporine or tacrolimus), which remains the standard of
care in most transplant programs. The trials also included
patients with varying risk of malignancy; some studies mandated
a history of cancer for inclusion, some excluded those with any
cancer, while others excluded only those with a history of
non-skin cancer. While these study differences added to the
heterogeneity of the analysis, they enhanced the generalizability
of our findings to a wider range of patients with different risks
of cancer. Fourth, included trials needed a minimum follow-up
of three months. While there is no accepted standard for time
needed to develop cancer after transplantation, we thought that
extending this to six or 12 months might exclude several trials
with important and contributable data. Fifth, this study was
funded by the manufacturer of sirolimus, which does open the
possibility of bias. Although the funding company was allowed
to review themanuscript before submission, the concept, design,
analysis, interpretation, and writing of this work was done solely
by the investigators. Finally, we limited our analysis to
randomized trials only. Generalizability of our finding could
be improved by the inclusion of non-randomized designs such
as cohort and case-control studies. The inclusion of such studies,
however, increases the risk of bias and heterogeneity that could
make data interpretation more difficult.56
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Conclusions
In conclusion, sirolimus use was associated with a reduction in
the risk of malignancy and non-melanoma skin cancer in patients
with kidney transplants. The benefit seemed most pronounced
when patients were converted from an established
immunosuppressive regimen to sirolimus, with fewer cancers
overall as well as fewer non-melanoma skin cancers and other
types of cancer. Given the increased risk of mortality, however,
the use of this drug does not seem warranted for most patients
with kidney transplant. Further research is needed to determine
if different populations, such as those at high risk of cancer,
might benefit from treatment with sirolimus after kidney
transplantation.
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Observational studies and some randomized trials suggest that the immunosuppressive drug sirolimus could reduce the incidence of
cancers
A previous meta-analysis found no significant association between sirolimus use and malignancy or death
What this study adds
An individual patient level meta-analysis of nearly 6000 kidney transplant recipients found that sirolimus significantly reduced malignancy
and non-melanoma skin cancer but increased death
Sirolimus can reduce the risk of cancer but the use of this drug does not seem warranted for most patients with kidney transplant given
the excess risk of mortality
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Tables
Table 1| Baseline characteristics of patients with kidney transplant according to immunosuppressive treatment group. Figures are numbers
(percentage) of patients unless stated otherwise
All (n=5876)Control group (n=2600)Sirolimus group (n=3276)Variable
Age (years):
45.4 (13.7)45.4 (13.8)45.4 (13.6)Mean (SD)
46.7 (35.0-56.0)46.4 (35.0-56.0)47.0 (35.0-56.0)Median (IQR)
Sex:
1938 (33.0)883 (34.0)1055 (32.2)Female
3938 (67.0)1717 (66.0)2221 (67.8)Male
Previous transplant:
5655 (96.2)2496 (96.0)3159 (96.4)No
220 (3.7)103 (4.0)117 (3.6)Yes
1 (0)1 (0)0 (0)Unknown
Region of enrolment:
2657 (45.2)1451 (55.8)1206 (36.8)Europe
1904 (32.4)524 (20.2)1380 (42.1)North America
740 (12.6)376 (14.5)364 (11.1)South America
327 (5.6)136 (5.2)191 (5.8)Oceania
154 (2.6)52 (2.0)102 (3.1)Africa
94 (1.6)61 (2.4)33 (1.0)Asia
Trial type:
4717 (80.3)2159 (83.0)2558 (78.1)De novo*




—341 (13.1)—Anti-metabolite and calcineurin inhibitor
—156 (6.0)—Placebo
IQR=interquartile range.
*Sirolimus or control agent given as initial immunosuppression.
†Sirolimus replacing another immunosuppressive agent.
‡Azathioprine or mycophenolate mofetil.
§Tacrolimus or cyclosporine.
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Table 2| Hazard ratios (95% confidence interval)* and P values for risk of cancer and death in patients with kidney transplant according to
immunosuppressive treatment group†
DeathOther cancerNon-melanoma skin cancerAny cancerVariable
1.001.001.001.00Control group
1.43 (1.21 to 1.71), <0.0011.05 (0.57 to 1.94), 0.880.44 (0.30 to 0.63), <0.0010.60 (0.39 to 0.93), 0.02Sirolimus group
1.07 (1.05 to 1.08), <0.0011.05 (1.02 to 1.08), <0.0011.08 (1.06 to 1.10), <0.0011.06 (1.04 to 1.09), <0.001Age‡
1.00 (0.80 to 1.25), 0.960.79 (0.55 to 1.13), 0.190.79 (0.57 to 1.10), 0.160.80 (0.66 to 0.97), 0.03Female sex




1.42 (0.91 to 2.20), 0.120.30 (0.08 to 1.12), 0.070.30 (0.06 to 1.62), 0.160.31 (0.23 to 0.41), <0.001Africa
1.74 (1.01 to 3.01), 0.0461.52 (0.84 to 2.78), 0.160.33 (0.04-3.05), 0.330.87 (0.58 to 1.30), 0.49Asia
1.23 (0.89 to 1.71), 0.210.87 (0.58 to 1.30), 0.490.44 (0.23 to 0.84), 0.010.58 (0.44 to 0.76), <0.001Europe
1.16 (0.65 to 2.07), 0.621.76 (1.13 to 2.73), 0.015.13 (2.64 to 9.98), <0.0013.68 (2.21 to 6.13), <0.001Oceania
1.67 (1.18 to 2.37), 0.0040.41 (0.24 to 0.70), 0.0010.74 (0.51 to 1.08), 0.120.59 (0.42 to 0.85), 0.004South America
*Calculated with Cox proportional hazards model. All models adjusted for trial, age, sex, geographic location of participant, and time after transplantation to
randomization.
†Three patients had both non-melanoma skin cancer and another cancer recorded on same date; each diagnosis was counted in relevant category.
‡Per year.
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Table 3| Aggregate relative risk of any cancer, non-melanoma skin cancer, and death in patients with kidney transplant from trials with
individual patient level data and trials with aggregate data*








1.28 (0.92 to 1.76)2025876210.48 (0.35 to 0.66)1505876210.69 (0.51 to 0.94)243587621Individual
patient level
data
1.15 (0.40 to 1.56)1604059290.46 (0.30 to 0.71)71251790.48 (0.29 to 0.79)116352116Aggregate
data
1.21 (0.97 to 1.51)3629935500.47 (0.37 to 0.61)2218393300.63 (0.48 to 0.81)359939737Combined
*Unadjusted risk calculated with random effects model.
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Table 4| Hazard ratios (95% confidence interval)* and P values for risk of cancer and death in patients with kidney transplant according to
immunosuppressive treatment group with follow-up censored at 24 months
DeathOther cancerNon-melanoma skin cancerAny cancerVariable
1.001.001.001.00Control group
1.38 (1.14 to 1.66), <0.0011.04 (0.51 to 2.12), 0.920.37 (0.22 to 0.62), <0.0010.55 (0.32 to 0.94), 0.03Sirolimus group
1.07 (1.05 to 1.08), <0.0011.05 (1.02 to 1.08), 0.0011.08 (1.06 to 1.10), <0.0011.06 (1.04 to 1.09), <0.001Age†
0.98 (0.77 to 1.24), 0.840.78 (0.52 to 1.16), 0.220.77 (0.49 to 1.18), 0.230.79 (0.63 to 0.99), 0.04Female sex




1.23 (0.73 to 2.24), 0.390.38 (0.17 to 0.87), 0.020.34 (0.04 to 2.62), 0.290.37 (0.19 to 0.71), 0.003Africa
1.63 (0.98 to 2.69), 0.061.66 (1.09 to 2.52), 0.02—‡0.68 (0.43 to 1.06), 0.09Asia
1.10 (0.81 to 1.49), 0.530.9 (0.63 to 1.28), 0.560.34 (0.18 to 0.63), <0.0010.52 (0.39 to 0.68), <0.001Europe
1.05 (0.52 to 2.12), 0.881.70 (1.01 to 2.88), 0.0474.23 (2.12 to 8.45), <0.0013.41 (1.99 to 5.83), <0.001Oceania
1.32 (0.75 to 2.34), 0.340.33 (0.12 to 0.89), 0.030.55 (0.32 to 0.95), 0.030.45 (0.28 to 0.73), 0.001South America
*Calculated with Cox proportional hazards model. All models adjusted for trial, age, sex, geographic location of participant, and time after transplantation to
randomization.
†Per year.
‡Hazard ratio not estimable; too few events.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g6679 doi: 10.1136/bmj.g6679 (Published 24 November 2014) Page 11 of 14
RESEARCH
Figures
Fig 1 PRISMA flow chart of included trials on effect of sirolimus on malignancy and survival after kidney transplantation
Fig 2 Time to first malignancy in patients with kidney transplant according to immunosuppressive treatment group
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Fig 3 Time to first non-melanoma skin cancer in patients with kidney transplant according to immunosuppressive treatment
group
Fig 4 Overall survival in patients with kidney transplant according to immunosuppressive treatment group
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Fig 5 Risk of cancer and death in patients with kidney transplant treated with sirolimus versus control
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